Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Arcadia Biosciences ( (RKDA) ) is now available.
On February 4, 2026, Arcadia Biosciences, Inc. announced that directors Albert D. Bolles, Ph.D., and Deborah Carosella resigned from the company’s board and from all subsidiary boards, effective the same day. The company stated that the departures were not due to any disagreement over operations, policies, practices or financial reporting, and both former directors agreed to remain available to assist Arcadia in an advisory capacity, suggesting an orderly governance transition rather than a sign of internal conflict.
The most recent analyst rating on (RKDA) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Arcadia Biosciences stock, see the RKDA Stock Forecast page.
Spark’s Take on RKDA Stock
According to Spark, TipRanks’ AI Analyst, RKDA is a Neutral.
The score is held down primarily by weak financial performance—ongoing large losses and persistent cash burn—while technicals also point to a bearish trend with the stock below key moving averages. A debt-free balance sheet and mixed corporate updates provide only limited offset, and valuation metrics are not supportive given the company’s unprofitability and lack of dividend data.
To see Spark’s full report on RKDA stock, click here.
More about Arcadia Biosciences
Average Trading Volume: 22,229
Technical Sentiment Signal: Sell
Current Market Cap: $3.29M
See more data about RKDA stock on TipRanks’ Stock Analysis page.